<?xml version='1.0'?><!DOCTYPE Annotation PUBLIC "//GENIA//DTD GENIA ANNOTATION EVENT 2.0//EN_Modified" "../ModifiedGENIAtypes/Modified_GENIA_event_20.dtd"><Annotation annotates="http://www.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;retmode=xml&amp;rettype=medline&amp;id=9384661" created="20/11/2006" creator="Yo Shidahara"><PubmedArticleSet><PubmedArticle><MedlineCitation>
<PMID>9384661</PMID>
<Article>
<ArticleTitle>
<sentence id="S1">Expression of <term id="T1" lex="c-fos" sem="DNA_molecule">c-fos</term> correlates with <term id="T2" lex="IFN-alpha_responsiveness" sem="Other"><term id="T3" lex="IFN-alpha" sem="Protein_molecule">IFN-alpha</term> responsiveness</term> in <term id="T4" lex="Philadelphia_chromosome_positive_chronic_myelogenous_leukemia" sem="Other"><term id="A1" sem="DNA_molecule">Philadelphia chromosome</term> positive chronic myelogenous leukemia</term>.</sentence>
<event KT="Other" id="E1">
<type class="Gene_expression"/>
<theme idref="T1"/>
<clue><clueType>Expression</clueType> <linkTheme>of</linkTheme> c-fos correlates with IFN-alpha responsiveness in Philadelphia chromosome positive chronic myelogenous leukemia.</clue>
</event>
<event KT="Other" id="E2">
<type class="Regulation"/>
<cause idref="T3"/>
<clue>Expression of c-fos correlates with IFN-alpha <clueType>responsiveness</clueType> in Philadelphia chromosome positive chronic myelogenous leukemia.</clue>
</event>
<event KT="Analysis" id="E3">
<type class="Correlation"/>
<theme idref="E1"/>
<theme idref="E2"/>
<clue>Expression of c-fos <clueType><clueKT>correlates</clueKT></clueType> <linkTheme>with</linkTheme> IFN-alpha responsiveness <clueLoc>in Philadelphia chromosome positive chronic myelogenous leukemia</clueLoc>.</clue>
</event>
</ArticleTitle>
<Abstract>
<AbstractText>
<sentence id="S2">This study evaluates (i) constitutive levels of <term id="T5" lex="oncogene" sem="RNA_molecule">oncogene</term> and <term id="T6" lex="p53_transcript" sem="RNA_family_or_group">p53</term> <term id="A2" sem="RNA_molecule">transcripts</term> in <term id="T7" lex="chronic_phase_CML_patient" sem="Multicellular_organism_natural">chronic phase CML patients</term> and (ii) their modulations subsequent to in vivo therapy with <term id="T8" lex="rIFN-alpha_2c" sem="Protein_molecule">rIFN-alpha 2c</term>.</sentence>
<event KT="Investigation" id="E4" uncertainty="doubtful">
<type class="Transcription"/>
<theme idref="T5" idref1="A2"/>
<clue>This study <clueKT>evaluates</clueKT> (i) constitutive <clueType>levels</clueType> <linkTheme>of</linkTheme> oncogene and p53 transcripts <clueLoc>in chronic phase CML patients</clueLoc> and (ii) their modulations subsequent to in vivo therapy with rIFN-alpha 2c.</clue>
<comment>NER T5,T6 MOD</comment></event>
<event KT="Investigation" id="E5" uncertainty="doubtful">
<type class="Transcription"/>
<theme idref="T6" idref1="A2"/>
<clue>This study <clueKT>evaluates</clueKT> (i) constitutive <clueType>levels</clueType> <linkTheme>of</linkTheme> oncogene and p53 transcripts <clueLoc>in chronic phase CML patients</clueLoc> and (ii) their modulations subsequent to in vivo therapy with rIFN-alpha 2c.</clue>
</event>
<sentence id="S3"><term id="T9" lex="peripheral_blood_mononuclear_cell" sem="Cell_natural">Peripheral blood mononuclear cells</term> (<term id="T10" lex="pbmc" sem="Cell_natural">pbmc</term>) and <term id="T11" lex="bone_marrow_cell" sem="Cell_natural">bone marrow cells</term> of 26 patients were examined for <cons id="T12" lex="(AND c-fos_mRNA_level c-myc_mRNA_level p53_mRNA_level the_hybrid_bcr/abl_mRNA_level)" sem="(AND Other Other Other Other)"><frag id="F1">c-fos</frag>, <frag id="F2">c-myc</frag>, <frag id="F3">p53</frag> and the <frag id="F4">hybrid bcr/abl</frag> <frag id="F5">mRNA</frag> <frag id="F6">levels</frag></cons>.</sentence>
<event KT="Investigation" id="E6" uncertainty="doubtful">
<type class="Transcription"/>
<theme idref="F1" idref1="F5"/>
<clue><clueLoc>Peripheral blood mononuclear cells (pbmc)</clueLoc> and bone marrow cells <clueLoc>of 26 patients</clueLoc> were <clueKT>examined</clueKT> for c-fos, c-myc, p53 and the hybrid bcr/abl mRNA <clueType>levels</clueType>.</clue>
</event>
<event KT="Investigation" id="E106" uncertainty="doubtful">
<type class="Transcription"/>
<theme idref="F1" idref1="F5"/>
<clue>Peripheral blood mononuclear cells (pbmc) and <clueLoc>bone marrow cells of 26 patients</clueLoc> were <clueKT>examined</clueKT> for c-fos, c-myc, p53 and the hybrid bcr/abl mRNA <clueType>levels</clueType>.</clue>
</event>
<event KT="Investigation" id="E7" uncertainty="doubtful">
<type class="Transcription"/>
<theme idref="F2" idref1="F5"/>
<clue><clueLoc>Peripheral blood mononuclear cells (pbmc)</clueLoc> and bone marrow cells <clueLoc>of 26 patients</clueLoc> were <clueKT>examined</clueKT> for c-fos, c-myc, p53 and the hybrid bcr/abl mRNA <clueType>levels</clueType>.</clue>
</event>
<event KT="Investigation" id="E107" uncertainty="doubtful">
<type class="Transcription"/>
<theme idref="F2" idref1="F5"/>
<clue>Peripheral blood mononuclear cells (pbmc) and <clueLoc>bone marrow cells of 26 patients</clueLoc> were <clueKT>examined</clueKT> for c-fos, c-myc, p53 and the hybrid bcr/abl mRNA <clueType>levels</clueType>.</clue>
</event>
<event KT="Investigation" id="E8" uncertainty="doubtful">
<type class="Transcription"/>
<theme idref="F3" idref1="F5"/>
<clue><clueLoc>Peripheral blood mononuclear cells (pbmc)</clueLoc> and bone marrow cells <clueLoc>of 26 patients</clueLoc> were <clueKT>examined</clueKT> for c-fos, c-myc, p53 and the hybrid bcr/abl mRNA <clueType>levels</clueType>.</clue>
</event>
<event KT="Investigation" id="E108" uncertainty="doubtful">
<type class="Transcription"/>
<theme idref="F3" idref1="F5"/>
<clue>Peripheral blood mononuclear cells (pbmc) and <clueLoc>bone marrow cells of 26 patients</clueLoc> were <clueKT>examined</clueKT> for c-fos, c-myc, p53 and the hybrid bcr/abl mRNA <clueType>levels</clueType>.</clue>
</event>
<event KT="Investigation" id="E9" uncertainty="doubtful">
<type class="Transcription"/>
<theme idref="F4" idref1="F5"/>
<clue><clueLoc>Peripheral blood mononuclear cells (pbmc)</clueLoc> and bone marrow cells <clueLoc>of 26 patients</clueLoc> were <clueKT>examined</clueKT> for c-fos, c-myc, p53 and the hybrid bcr/abl mRNA <clueType>levels</clueType>.</clue>
</event>
<event KT="Investigation" id="E109" uncertainty="doubtful">
<type class="Transcription"/>
<theme idref="F4" idref1="F5"/>
<clue>Peripheral blood mononuclear cells (pbmc) and <clueLoc>bone marrow cells of 26 patients</clueLoc> were <clueKT>examined</clueKT> for c-fos, c-myc, p53 and the hybrid bcr/abl mRNA <clueType>levels</clueType>.</clue>
</event>
<sentence id="S4">Results indicated that (i) constitutive <term id="T13" lex="c-fos_transcript_level" sem="Other"><term id="T14" lex="c-fos_transcript" sem="RNA_molecule">c-fos transcript</term> levels</term> are significantly higher in <term id="T15" lex="patient" sem="Multicellular_organism_natural">patients</term> subsequently responding to <term id="T16" lex="IFN-alpha_therapy" sem="Other"><term id="T17" lex="IFN-alpha" sem="Protein_molecule">IFN-alpha</term> therapy</term> (p &lt; 0.01) and positively correlated with the proportion of <term id="T18" lex="lymphocyte" sem="Cell_natural">lymphocytes</term> (r = 0.6895, p &lt; 0.01) and negatively with the proportion of <term id="T19" lex="immature_cell" sem="Cell_natural">immature cells</term> (r = -0.568, p &lt; 0.01) contained in the <term id="T20" lex="pbmc" sem="Cell_natural">pbmc</term> preparations tested, (ii) <term id="T21" lex="constitutive_mRNA_levels" sem="Other"><term id="T22" lex="constitutive_mRNA" sem="RNA_family_or_group">constitutive mRNA</term> levels</term> <term id="A10" sem="RNA_molecule">of</term> the <term id="T23" lex="hybrid_bcr/abl" sem="RNA_molecule">hybrid bcr/abl</term>, <term id="T24" lex="c-myc" sem="RNA_molecule">c-myc</term> and <term id="T25" lex="p53" sem="RNA_molecule">p53</term> are positively correlated with each other, but failed to relate to <term id="A8" sem="Other">disease parameters</term>, and (iii) acute and chronic in vivo exposure to <term id="T26" lex="IFN-alpha" sem="Protein_molecule">IFN-alpha</term> is accompanied by upregulation of <term id="T27" lex="c-fos" sem="RNA_molecule">c-fos</term> and downregulation of <term id="T29" lex="c-myc_mRNA_level" sem="Other"><term id="T30" lex="c-myc_mRNA" sem="RNA_molecule">c-myc</term> <term id="A9" sem="RNA_molecule">mRNA</term> levels</term> in <term id="T31" lex="responder_patient" sem="Multicellular_organism_natural">responder <term id="T32" lex="patient" sem="Multicellular_organism_natural">patients</term></term>.</sentence>
<event KT="Other" id="E10">
<type class="Transcription"/>
<theme idref="T14"/>
<clue>Results indicated that (i) constitutive c-fos transcript <clueType>levels</clueType> are significantly higher <clueLoc>in patients</clueLoc> subsequently responding to IFN-alpha therapy (p &lt; 0.01) and positively correlated with the proportion of lymphocytes (r = 0.6895, p &lt; 0.01) and negatively with the proportion of immature cells (r = -0.568, p &lt; 0.01) contained in the pbmc preparations tested, (ii) constitutive mRNA levels of the hybrid bcr/abl, c-myc and p53 are positively correlated with each other, but failed to relate to disease parameters, and (iii) acute and chronic in vivo exposure to IFN-alpha is accompanied by upregulation of c-fos and downregulation of c-myc mRNA levels in responder patients.</clue>
<comment>NER T23,T24,T25,T27,T30 MOD</comment></event>
<event CL="L2" KT="Analysis" Manner="High" id="E11">
<type class="Positive_regulation"/>
<theme idref="E10"/>
<cause idref="T17"/>
<clue>Results <clueKT><clueCL>indicated</clueCL></clueKT> that (i) constitutive c-fos transcript levels are <clueManner>significantly</clueManner> <clueType><clueManner>higher</clueManner></clueType> in patients subsequently <linkCause>responding to</linkCause> IFN-alpha therapy (p &lt; 0.01) and positively correlated with the proportion of lymphocytes (r = 0.6895, p &lt; 0.01) and negatively with the proportion of immature cells (r = -0.568, p &lt; 0.01) contained in the pbmc preparations tested, (ii) constitutive mRNA levels of the hybrid bcr/abl, c-myc and p53 are positively correlated with each other, but failed to relate to disease parameters, and (iii) acute and chronic in vivo exposure to IFN-alpha is accompanied by upregulation of c-fos and downregulation of c-myc mRNA levels in responder patients.</clue>
</event>
<event CL="L2" KT="Analysis" id="E12">
<type class="Correlation"/>
<theme idref="E10"/>
<theme idref="T18"/>
<clue>Results <clueCL>indicated</clueCL> that (i) constitutive c-fos transcript levels are significantly higher in patients subsequently responding to IFN-alpha therapy (p &lt; 0.01) and <clueType>positively <clueKT>correlated</clueKT></clueType> <linkTheme>with</linkTheme> the proportion of lymphocytes (r = 0.6895, p &lt; 0.01) and negatively with the proportion of immature cells (r = -0.568, p &lt; 0.01) contained <clueLoc>in the pbmc preparations tested</clueLoc>, (ii) constitutive mRNA levels of the hybrid bcr/abl, c-myc and p53 are positively correlated with each other, but failed to relate to disease parameters, and (iii) acute and chronic in vivo exposure to IFN-alpha is accompanied by upregulation of c-fos and downregulation of c-myc mRNA levels in responder patients.</clue>
</event>
<event CL="L2" KT="Analysis" id="E13">
<type class="Correlation"/>
<theme idref="E10"/>
<theme idref="T19"/>
<clue>Results <clueCL>indicated</clueCL> that (i) constitutive c-fos transcript levels are significantly higher in patients subsequently responding to IFN-alpha therapy (p &lt; 0.01) and positively <clueType><clueKT>correlated</clueKT></clueType> with the proportion of lymphocytes (r = 0.6895, p &lt; 0.01) and <clueType>negatively</clueType> <linkTheme>with</linkTheme> the proportion of immature cells (r = -0.568, p &lt; 0.01) contained <clueLoc>in the pbmc preparations tested</clueLoc>, (ii) constitutive mRNA levels of the hybrid bcr/abl, c-myc and p53 are positively correlated with each other, but failed to relate to disease parameters, and (iii) acute and chronic in vivo exposure to IFN-alpha is accompanied by upregulation of c-fos and downregulation of c-myc mRNA levels in responder patients.</clue>
</event>
<event CL="L2" KT="Analysis" id="E14">
<type class="Correlation"/>
<theme idref="T22" idref1="A10" idref2="T23"/>
<theme idref="T22" idref1="A10" idref2="T24"/>
<theme idref="T22" idref1="A10" idref2="T25"/>
<clue>Results <clueCL>indicated</clueCL> that (i) constitutive c-fos transcript levels are significantly higher in patients subsequently responding to IFN-alpha therapy (p &lt; 0.01) and positively correlated with the proportion of lymphocytes (r = 0.6895, p &lt; 0.01) and negatively with the proportion of immature cells (r = -0.568, p &lt; 0.01) contained in the pbmc preparations tested, (ii) constitutive mRNA levels of the hybrid bcr/abl, c-myc and p53 are <clueType>positively <clueKT>correlated</clueKT></clueType> <linkTheme>with</linkTheme> <corefTheme>each other</corefTheme>, but failed to relate to disease parameters, and (iii) acute and chronic in vivo exposure to IFN-alpha is accompanied by upregulation of c-fos and downregulation of c-myc mRNA levels in responder patients.</clue>
</event>
<event CL="L2" KT="Analysis" Polarity="Negative" assertion="non-exist" id="E15">
<type class="Correlation"/>
<theme idref="T22" idref1="A10" idref2="T23"/>
<theme idref="A8"/>
<clue>Results <clueKT><clueCL>indicated</clueCL></clueKT> that (i) constitutive c-fos transcript levels are significantly higher in patients subsequently responding to IFN-alpha therapy (p &lt; 0.01) and positively correlated with the proportion of lymphocytes (r = 0.6895, p &lt; 0.01) and negatively with the proportion of immature cells (r = -0.568, p &lt; 0.01) contained in the pbmc preparations tested, (ii) constitutive mRNA levels of the hybrid bcr/abl, c-myc and p53 are positively correlated with each other, but <clueType><cluePolarity>failed</cluePolarity> to relate</clueType> <linkTheme>to</linkTheme> disease parameters, and (iii) acute and chronic in vivo exposure to IFN-alpha is accompanied by upregulation of c-fos and downregulation of c-myc mRNA levels in responder patients.</clue>
</event>
<event CL="L2" KT="Analysis" id="E16">
<type class="Positive_regulation"/>
<theme idref="T27" idref1="A9"/>
<cause idref="T26"/>
<clue>Results <clueKT><clueCL>indicated</clueCL></clueKT> that (i) constitutive c-fos transcript levels are significantly higher in patients subsequently responding to IFN-alpha therapy (p &lt; 0.01) and positively correlated with the proportion of lymphocytes (r = 0.6895, p &lt; 0.01) and negatively with the proportion of immature cells (r = -0.568, p &lt; 0.01) contained in the pbmc preparations tested, (ii) constitutive mRNA levels of the hybrid bcr/abl, c-myc and p53 are positively correlated with each other, but failed to relate to disease parameters, and (iii) acute and chronic in vivo exposure to IFN-alpha is <clueType>accompanied by upregulation</clueType> <linkTheme>of</linkTheme> c-fos and downregulation of c-myc mRNA levels <clueLoc>in responder patients</clueLoc>.</clue>
</event>
<event CL="L2" KT="Analysis" id="E17">
<type class="Negative_regulation"/>
<theme idref="T30" idref1="A9"/>
<cause idref="T26"/>
<clue>Results <clueKT><clueCL>indicated</clueCL></clueKT> that (i) constitutive c-fos transcript levels are significantly higher in patients subsequently responding to IFN-alpha therapy (p &lt; 0.01) and positively correlated with the proportion of lymphocytes (r = 0.6895, p &lt; 0.01) and negatively with the proportion of immature cells (r = -0.568, p &lt; 0.01) contained in the pbmc preparations tested, (ii) constitutive mRNA levels of the hybrid bcr/abl, c-myc and p53 are positively correlated with each other, but failed to relate to disease parameters, and (iii) acute and chronic in vivo exposure to IFN-alpha is <clueType>accompanied by</clueType> upregulation of c-fos and <clueType>downregulation</clueType> <linkTheme>of</linkTheme> c-myc mRNA levels <clueLoc>in responder patients</clueLoc>.</clue>
</event>
</AbstractText>
</Abstract></Article></MedlineCitation></PubmedArticle></PubmedArticleSet></Annotation>
